|
05 May 2020 |
TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia
|
|
04 May 2020 |
Lupin Announces Positive Topline Results From its Phase 3 Study of Single-Dose Solosec® (secnidazole) for the Treatment of Trichomoniasis
|
|
04 May 2020 |
Newron Reports Top-Line Results from its STARS Study Evaluating Sarizotan in Patients with Rett Syndrome
|
|
02 May 2020 |
Gilead’s Investigational Antiviral Remdesivir Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19
|
|
01 May 2020 |
Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients
|
|
01 May 2020 |
ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer
|
|
01 May 2020 |
Sosei Heptares Notes That Enerzair® Breezhaler® (QVM149) has been Recommended for Approval in the European Union for Treating Uncontrolled Asthma
|
|
01 May 2020 |
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR Gene
|
|
01 May 2020 |
Pierre Fabre receives positive CHMP opinion for BRAFTOVI® (encorafenib) in combination with cetuximab for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer
|
|
01 May 2020 |
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Application for CC-486 for Maintenance Treatment of Adult Patients in Remission with Acute Myeloid Leukemia
|
|
30 Apr 2020 |
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
|
|
30 Apr 2020 |
FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status
|
|
29 Apr 2020 |
Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19
|
|
29 Apr 2020 |
Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19
|
|
29 Apr 2020 |
Vicore Pharma gets regulatory approval to start phase II clinical trial with VP01 (C21) in patients with COVID-19, SARS CoV-2 infection
|
|
29 Apr 2020 |
Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias
|
|
29 Apr 2020 |
Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
|
|
28 Apr 2020 |
Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response
|
|
28 Apr 2020 |
ORIC Pharmaceuticals Presents Preclinical Data on CD73 Inhibitor at the American Association for Cancer Research (AACR) Virtual Annual Meeting
|
|
28 Apr 2020 |
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson’s Disease Experiencing “Off” Episodes
|
|
28 Apr 2020 |
BioXcel Therapeutics Announces Initiation of a Phase 2 Study of BXCL701 in Combination with a PD-1 Inhibitor for Treatment Emergent Neuroendocrine Prostate Cancer
|
|
28 Apr 2020 |
Sovateltide significantly (p=0.0157) improved clinical outcome (modified Rankin Scale) in patients with acute cerebral ischemic stroke when compared to standard of care
|
|
28 Apr 2020 |
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
|
|
28 Apr 2020 |
Tarveda Therapeutics Presents Pharmacokinetic and Tumor Biopsy Data from First in Human Study of PEN-866 at the 2020 AACR Virtual Annual Meeting
|
|
28 Apr 2020 |
Shionogi Receives European Commission Marketing Authorisation for FETCROJA® (cefiderocol) for the Treatment of Infections Due to Aerobic Gram-negative Bacteria in Adults With Limited Treatment Options
|
